Literature DB >> 12791308

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Esther F A Brandon1, Christiaan D Raap, Irma Meijerman, Jos H Beijnen, Jan H M Schellens.   

Abstract

The liver is the predominant organ in which biotransformation of foreign compounds takes place, although other organs may also be involved in drug biotransformation. Ideally, an in vitro model for drug biotransformation should accurately resemble biotransformation in vivo in the liver. Several in vitro human liver models have been developed in the past few decades, including supersomes, microsomes, cytosol, S9 fraction, cell lines, transgenic cell lines, primary hepatocytes, liver slices, and perfused liver. A general advantage of these models is a reduced complexity of the study system. On the other hand, there are several more or less serious specific drawbacks for each model, which prevents their widespread use and acceptance by the regulatory authorities as an alternative for in vivo screening. This review describes the practical aspects of selected in vitro human liver models with comparisons between the methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791308     DOI: 10.1016/s0041-008x(03)00128-5

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  78 in total

1.  In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignacio Manzanares; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

2.  A novel 3D liver organoid system for elucidation of hepatic glucose metabolism.

Authors:  Yanhua Lu; Guoliang Zhang; Chong Shen; Korkut Uygun; Martin L Yarmush; Qin Meng
Journal:  Biotechnol Bioeng       Date:  2011-10-19       Impact factor: 4.530

3.  Precision-cut tissue chips as an in vitro toxicology system.

Authors:  J M Catania; A M Pershing; A J Gandolfi
Journal:  Toxicol In Vitro       Date:  2007-02-13       Impact factor: 3.500

4.  In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.

Authors:  Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

5.  Development and evaluation of an in vivo assay in Caenorhabditis elegans for screening of compounds for their effect on cytochrome P450 expression.

Authors:  Baby P S Chakrapani; Sandeep Kumar; Jamuna R Subramaniam
Journal:  J Biosci       Date:  2008-06       Impact factor: 1.826

6.  Use of high-throughput enzyme-based assay with xenobiotic metabolic capability to evaluate the inhibition of acetylcholinesterase activity by organophosphorous pesticides.

Authors:  Shuaizhang Li; Jinghua Zhao; Ruili Huang; Michael F Santillo; Keith A Houck; Menghang Xia
Journal:  Toxicol In Vitro       Date:  2019-01-06       Impact factor: 3.500

Review 7.  Microfabricated mammalian organ systems and their integration into models of whole animals and humans.

Authors:  Jong H Sung; Mandy B Esch; Jean-Matthieu Prot; Christopher J Long; Alec Smith; James J Hickman; Michael L Shuler
Journal:  Lab Chip       Date:  2013-04-07       Impact factor: 6.799

8.  Prasugrel metabolites inhibit neutrophil functions.

Authors:  Elisabetta Liverani; Mario C Rico; Analia E Garcia; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  J Pharmacol Exp Ther       Date:  2012-10-24       Impact factor: 4.030

9.  Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system.

Authors:  Dhanuka P Wasalathanthri; Ronaldo C Faria; Spundana Malla; Amit A Joshi; John B Schenkman; James F Rusling
Journal:  Analyst       Date:  2012-10-25       Impact factor: 4.616

10.  A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS.

Authors:  Venkateswaran C Pillai; Stephen C Strom; Steve N Caritis; Raman Venkataramanan
Journal:  J Pharm Biomed Anal       Date:  2012-10-22       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.